- Previous Close
2.200 - Open
2.200 - Bid 2.180 x --
- Ask 2.290 x --
- Day's Range
2.180 - 2.200 - 52 Week Range
1.700 - 2.450 - Volume
3,000 - Avg. Volume
78,783 - Market Cap (intraday)
2.544B - Beta (5Y Monthly) 0.29
- PE Ratio (TTM)
15.57 - EPS (TTM)
0.140 - Earnings Date Mar 28, 2025
- Forward Dividend & Yield 0.11 (4.81%)
- Ex-Dividend Date Jun 3, 2025
- 1y Target Est
--
Shanghai Pioneer Holding Ltd, an investment holding company, markets, promotes, and sells pharmaceutical products and medical devices primarily in the People's Republic of China. The company offers pharmaceutical products for ophthalmology, pain management, cardiovascular, immunology, gynecology, gastroenterology, and other therapeutic areas. It also sells medical devices, including ophthalmology, orthopedics, odontology, and wound care products. In addition, the company engages in sale of ancillary tools, dental devices, and imported in-licensed prescription products, as well as accessories leasing; research and development of denture and implants dentistry; Medical research and experimental development; and provision of metal finishing services. It sells its products to hospitals and medical institutions, and pharmacies. The company was formerly known as China Pioneer Pharma Holdings Limited. Shanghai Pioneer Holding Ltd was founded in 1996 and is headquartered in Shanghai, the People's Republic of China. Shanghai Pioneer Holding Ltd is a subsidiary of Pioneer Pharma (BVI) Co., Ltd.
www.pioneer-pharma.com335
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: 1345.HK
View MorePerformance Overview: 1345.HK
Trailing total returns as of 4/11/2025, which may include dividends or other distributions. Benchmark is HANG SENG INDEX (^HSI) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 1345.HK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 1345.HK
View MoreValuation Measures
Market Cap
2.54B
Enterprise Value
2.51B
Trailing P/E
15.88
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.57
Price/Book (mrq)
2.17
Enterprise Value/Revenue
1.56
Enterprise Value/EBITDA
11.05
Financial Highlights
Profitability and Income Statement
Profit Margin
9.90%
Return on Assets (ttm)
7.80%
Return on Equity (ttm)
13.63%
Revenue (ttm)
1.53B
Net Income Avi to Common (ttm)
151.62M
Diluted EPS (ttm)
0.140
Balance Sheet and Cash Flow
Total Cash (mrq)
103.57M
Total Debt/Equity (mrq)
6.74%
Levered Free Cash Flow (ttm)
96.06M